These findings were also confirmed by multivariate analysis which indicated that trastuzumab addition to NAC (HR = 2.933) and an ER-poor status (HR = 2.873) may be related factors for predicting a higher pNNR after NAC in HER2-positive breast cancer (Fig. 2). This evidence concerns the gene ESR1 and breast carcinoma.